Vistagen Therapeutics (VTGN) Capital Expenditures Growth (1y) (2011 - 2025)
Vistagen Therapeutics (VTGN) Capital Expenditures Growth (1y) (2011 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1,133.33% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -37.81% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 142.64% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.37% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -73.62% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 22,433.30% |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 38.83% |
| Sep 30, 2025 | 24.00% |
| Jun 30, 2025 | -13.33% |
| Mar 31, 2025 | -1,036.36% |
| Dec 31, 2024 | 472.22% |
| Mar 31, 2024 | -97.92% |
| Dec 31, 2023 | 109.02% |
| Mar 31, 2023 | 363.60% |
| Dec 31, 2022 | -199,400.00% |
| Sep 30, 2022 | -87.82% |
| Jun 30, 2022 | 16.81% |
| Mar 31, 2022 | -885.49% |
| Dec 31, 2021 | -100.07% |
| Sep 30, 2021 | 102.83% |
| Sep 30, 2018 | 8,500.00% |
| Dec 31, 2017 | 45.45% |
| Sep 30, 2017 | -128.07% |
| Mar 31, 2017 | 956.22% |
| Mar 31, 2014 | -107.20% |
| Mar 31, 2013 | 1,302.63% |